Therefore, IL-17 appears to be a pleiotropic cytokine that acts as a protumor or antitumor activator in cancer development and this action depends on the immunogenicity of tumor models (Benchetrit et al. 2002). The gene discussed is IL17A; the disease is neoplasm.